News
SDZNY
88.40
-2.18%
-1.97
Barclays Sticks to Its Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 8h ago
Sandoz reiterates FY 2026 constant-currency sales growth outlook of mid-to-high single digits in pre-close brief
PUBT · 1d ago
UPDATE 1-Hybio's generic weight-loss drug set for FDA review
Reuters · 1d ago
Sandoz announces U.S. FDA accepted for review two ANDAs for tirzepatide
TipRanks · 2d ago
Weekly Report: what happened at SDZNY last week (0622-0626)?
Weekly Report · 2d ago
FDA set to review Sandoz's generic GLP-1s
Reuters · 2d ago
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)
Seeking Alpha · 06/23 16:55
Weekly Report: what happened at SDZNY last week (0615-0619)?
Weekly Report · 06/22 09:49
Sandoz to host capital markets day for investors and analysts
PUBT · 06/22 05:00
Weekly Report: what happened at SDZNY last week (0608-0612)?
Weekly Report · 06/15 09:50
Weekly Report: what happened at SDZNY last week (0601-0605)?
Weekly Report · 06/08 09:48
FACTBOX-Major investment pledges at Choose France summit
Reuters · 06/01 13:35
Weekly Report: what happened at SDZNY last week (0525-0529)?
Weekly Report · 06/01 09:50
PRESS DIGEST-Financial Times - June 1
Reuters · 05/31 23:58
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs
Seeking Alpha · 05/27 11:27
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position
Reuters · 05/27 06:23
Weekly Report: what happened at SDZNY last week (0518-0522)?
Weekly Report · 05/25 09:52
Hims & Hers launches generics for Novo’s semaglutide in Canada
Seeking Alpha · 05/21 13:29
Weekly Report: what happened at SDZNY last week (0511-0515)?
Weekly Report · 05/18 09:52
Sandoz confirms the EC granted marketing authorization for Bysumlog, Dazparda
TipRanks · 05/15 12:01
More
Webull provides a variety of real-time SDZNY stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZNY
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.